Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Sinem Ornek & Emek Kocaturk. (2021) A patient-oriented approach to long-term use of omalizumab in chronic spontaneous urticaria. Cutaneous and Ocular Toxicology 40:4, pages 305-311.
Read now
Read now
Andac Salman, Tulin Ergun & Ana Maria Gimenez-Arnau. (2020) Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study. Journal of Dermatological Treatment 31:2, pages 204-209.
Read now
Read now
Jonathan A. Bernstein, Abhishek Kavati, Michael D. Tharp, Benjamin Ortiz, Karen MacDonald, Kris Denhaerynck & Ivo Abraham. (2018) Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘real-world’ evidence. Expert Opinion on Biological Therapy 18:4, pages 425-448.
Read now
Read now
Ana M Giménez-Arnau. (2017) Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety. Expert Opinion on Biological Therapy 17:3, pages 375-385.
Read now
Read now
Marcus Maurer, Gino A. Vena, Nicoletta Cassano & Torsten Zuberbier. (2016) Current and future therapies for treating chronic spontaneous urticaria. Expert Opinion on Pharmacotherapy 17:8, pages 1131-1139.
Read now
Read now
Moises Labrador-Horrillo & Marta Ferrer. (2015) Profile of omalizumab in the treatment of chronic spontaneous urticaria. Drug Design, Development and Therapy 9, pages 4909-4915.
Read now
Read now
Riccardo Asero, Elena Pinter, Alessandro Maria Marra, Alberto Tedeschi, Massimo Cugno & Angelo Valerio Marzano. (2015) Current challenges and controversies in the management of chronic spontaneous urticaria. Expert Review of Clinical Immunology 11:10, pages 1073-1082.
Read now
Read now
Torsten Zuberbier & Marcus Maurer. (2015) Omalizumab for the treatment of chronic urticaria. Expert Review of Clinical Immunology 11:2, pages 171-180.
Read now
Read now
Articles from other publishers (46)
Andrey E. Shulzhenko, Leya E. Sorokina, Elena V. Kovalkova, Elizaveta V. Kuznetsova & Daria S. Fomina. (2023) Comparative analysis of clinical efficacy and safety of omalizumab biosimilar in the treatment of patients with chronic spontaneous urticaria. Russian Journal of Allergy 20:3, pages 309-320.
Crossref
Crossref
Rita Brás, Célia Costa, Rita Limão, Leonor Esteves Caldeira, Marisa Paulino & Elisa Pedro. (2023) Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation. The Journal of Allergy and Clinical Immunology: In Practice 11:8, pages 2392-2402.
Crossref
Crossref
Dorothea Terhorst-Molawi, Lena Fox, Frank Siebenhaar, Martin Metz & Marcus Maurer. (2023) Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know. American Journal of Clinical Dermatology 24:3, pages 397-404.
Crossref
Crossref
Ao Wang, Yuhui Yun, Zhihua Wen, Yingxia Gao, Shuzhen Qi, Yu Zhang, Yunsheng Liang & Xu Yao. (2022) Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China. World Allergy Organization Journal 15:12, pages 100719.
Crossref
Crossref
Olguța Anca Orzan, Liliana Gabriela Popa, Mara Mădălina Mihai, Anca Cojocaru, Călin Giurcăneanu & Alexandra Maria Dorobanțu. (2022) Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies. Medicina 58:6, pages 816.
Crossref
Crossref
Patrizia Pepe & Victor Desmond Mandel. 2021. Urticaria - Diagnosis and Management. Urticaria - Diagnosis and Management.
Melanie Mitsui Wong & Paul Kevin Keith. (2020) Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review. Allergy, Asthma & Clinical Immunology 16:1.
Crossref
Crossref
Ozlem Su, Anil Gulsel Bahali & Nahide Onsun. (2020) The effect of at least 1‐year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria. Dermatologic Therapy 33:6.
Crossref
Crossref
Marcus Maurer, Celia Costa, AnaMaria Gimenez Arnau, Gerard Guillet, Moises Labrador‐Horrillo, Hilde Lapeere, Raisa Meshkova, Sinisa Savic & Nadine Chapman‐Rothe. (2020) Antihistamine‐resistant chronic spontaneous urticaria remains undertreated: 2‐year data from the AWARE study. Clinical & Experimental Allergy 50:10, pages 1166-1175.
Crossref
Crossref
Martin Metz, Zahava Vadasz, Emek Kocatürk & Ana M. Giménez-Arnau. (2020) Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence. Clinical Reviews in Allergy & Immunology 59:1, pages 38-45.
Crossref
Crossref
Sevim Baysak, Aysegul Sevim Kecici & Bilal Dogan. (2020) Long‐term follow‐up effect of omalizumab in chronic spontaneous urticaria and its association with serum C‐reactive protein levels. Dermatologic Therapy 33:4.
Crossref
Crossref
Riccardo Asero, Angelo V. Marzano & Massimo Cugno. (2020) Unresponsiveness to Omalizumab in Chronic Spontaneous Urticaria. Current Treatment Options in Allergy 7:2, pages 135-141.
Crossref
Crossref
M. Alcántara Villar, J.C. Armario Hita, S. Cimbollek, M.D. Fernández Ballesteros, M. Galán Gutiérrez, C. Hernández Montoya, M.Á. Lara-Jiménez, J.J. Pereyra Rodríguez, J.M. Vega Chicote & R. Ruiz-Villaverde. (2020) A Review of the Latest Recommendations on the Management of Chronic Urticaria: A Multidisciplinary Consensus Statement From Andalusia, Spain. Actas Dermo-Sifiliográficas (English Edition) 111:3, pages 222-228.
Crossref
Crossref
M. Alcántara Villar, J.C. Armario Hita, S. Cimbollek, M.D. Fernández Ballesteros, M. Galán Gutiérrez, C. Hernández Montoya, M.Á. Lara-Jiménez, J.J. Pereyra Rodríguez, J.M. Vega Chicote & R. Ruiz-Villaverde. (2020) Revisión de las últimas novedades en el manejo del paciente con urticaria crónica: Consenso multidisciplinar de la comunidad autónoma de Andalucía. Actas Dermo-Sifiliográficas 111:3, pages 222-228.
Crossref
Crossref
Amanda P. McIntyre, Ravi K. Viswanathan, Mark H. Moss & Sameer K. Mathur. (2020) Real-world dosing of omalizumab for chronic spontaneous urticaria. Annals of Allergy, Asthma & Immunology 124:2, pages 211-212.
Crossref
Crossref
Jeong-Hee Choi, Dong Hun Lee, Woo-Jung Song, Mira Choi, Jae-Woo Kwon, Gun-Woo Kim, Myung Hwa Kim, Mi-Ae Kim, Min-Hye Kim, Byung-Keun Kim, Sujeong Kim, Joung Soo Kim, Jung Eun Kim, Ju-Young Kim, Joo-Hee Kim, Hyun Jung Kim, Hye One Kim, Hyo-Bin Kim, Joo Young Roh, Kyung Hee Park, Kui Young Park, Han-Ki Park, Hyunsun Park, Jung Min Bae, Ji Yeon Byun, Dae Jin Song, Young Min Ahn, Seung Eun Lee, Young Bok Lee, Joong Sun Lee, Ji Hyun Lee, Kyung-Hwan Lim, Sang Woong Youn, Yoon-Seok Chang, You Hoon Jeon, Jiehyun Jeon, Mihn-Sook Jue, Sun Hee Choi, Gyu-Young Hur, Dae Hyun Lim, Young-Min Ye & Young Min Park. (2020) The KAAACI/KDA Evidence-Based Practice Guidelines for Chronic Spontaneous Urticaria in Korean Adults and Children: Part 2. Management of H1-Antihistamine-Refractory Chronic Urticaria. Allergy, Asthma & Immunology Research 12:5, pages 750.
Crossref
Crossref
Murat Türk, Leonor Carneiro-Leão, Pavel Kolkhir, Hanna Bonnekoh, Thomas Buttgereit & Marcus Maurer. (2020) How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers. The Journal of Allergy and Clinical Immunology: In Practice 8:1, pages 113-124.
Crossref
Crossref
Todor A. Popov, Martin K. Church, George Christoff & Marcus Maurer. (2019) Angioedema and prescribing of omalizumab for chronic urticaria in countries with limited financial resources. World Allergy Organization Journal 12:11, pages 100079.
Crossref
Crossref
X. Cubiró, J. Spertino, E. Rozas-Muñoz, E. Serra-Baldrich & L. Puig. (2019) The Effectiveness of Omalizumab Treatment in Real-Life is Lower in Patients with Chronic Urticaria Longer than 18 Months’ Evolution and Prior Immunosuppressive Treatment. Actas Dermo-Sifiliográficas (English Edition) 110:4, pages 289-296.
Crossref
Crossref
X. Cubiró, J. Spertino, E. Rozas-Muñoz, E. Serra-Baldrich & L. Puig. (2019) La efectividad del tratamiento con omalizumab en la vida real es menor en pacientes con urticaria crónica de más de 18 meses de evolución y tratamiento inmunosupresor previo. Actas Dermo-Sifiliográficas 110:4, pages 289-296.
Crossref
Crossref
Gamze Serarslan, Mehmet Uzun, Asena Çiğdem Doğramacı & Ebru Çelik. (2019) Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: A retrospective study. Dermatologic Therapy 32:1, pages e12752.
Crossref
Crossref
A. Hamelin, E. Amsler, P. Mathelier-Fusade, C. Pecquet, O. Bayrou, A. Barbaud & A. Soria. (2019) Traitement de l’urticaire chronique par omalizumab : données en vie réelle. Annales de Dermatologie et de Vénéréologie 146:1, pages 9-18.
Crossref
Crossref
Michael D. Tharp, Jonathan A. Bernstein, Abhishek Kavati, Benjamin Ortiz, Karen MacDonald, Kris Denhaerynck, Ivo Abraham & Christopher S. Lee. (2019) Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria. JAMA Dermatology 155:1, pages 29.
Crossref
Crossref
J. Spertino, L. Curto Barredo, E. Rozas Muñoz, I. Figueras Nart, E. Serra Baldrich, M. Bonfill-Ortí, V. Expósito-Serrano, A. Guilabert, G. Melé Ninot, M. Villar Buil, J. Garcias Ladaria, X. García Navarro, M. Vilavella, I. Bielsa Marsol, G. Aparicio Ortiz, C. Baliu Piqué, A. Álvarez Abella, N. Lamas Domenech, J.M. Mascaró, S. Gómez, J.I. Torné Gutiérrez, A. Vicente Villa & A. Gimenez Arnau. (2018) Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab. Actas Dermo-Sifiliográficas (English Edition) 109:9, pages 771-776.
Crossref
Crossref
J. Spertino, L. Curto Barredo, E. Rozas Muñoz, I. Figueras Nart, A. Gimenez Arnau, E. Serra Baldrich, M. Bonfill-Ortí, V. Expósito-Serrano, A. Guilabert, G. Melé Ninot, M. Villar Buil, J. Garcias Ladaria, X. García Navarro, M. Vilavella, I. Bielsa Marsol, G. Aparicio Ortiz, C. Baliu Piqué, A. Álvarez Abella, N. Lamas Domenech, J.M. Mascaró, S. Gómez, J.I. Torné Gutiérrez, A. Vicente Villa & A. Gimenez Arnau. (2018) Algoritmo de tratamiento con omalizumab en urticaria crónica espontánea. Actas Dermo-Sifiliográficas 109:9, pages 771-776.
Crossref
Crossref
Victor D. Mandel, Mario B. Guanti, Serena Liberati, Antongiulio Demonte, Giovanni Pellacani & Patrizia Pepe. (2018) Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies. Dermatology and Therapy 8:2, pages 291-301.
Crossref
Crossref
Isil Bulur, Emel Bulbul Baskan, Mustafa Ozdemir, Ali Balevi, Emek Kocatürk Göncü, Ilknur Altunay, Müzeyyen Gönül, Can Ergin, İlgen Ertam, Hilal Kaya Erdoğan, Muzaffer Bilgin & Muzaffer Mustafa Teoman. (2018) The efficacy and safety of omalizumab in refractory chronic spontaneous urticaria: real-life experience in Turkey. Acta Dermatovenerologica Alpina Pannonica et Adriatica 27:3.
Crossref
Crossref
M. Ferrer & R. Madamba. (2017) Biologics in chronic urticaria. Allergologia et Immunopathologia 45, pages 41-44.
Crossref
Crossref
M. Pinto Gouveia, A. Gameiro, A. Pinho & M. Gonçalo. (2017) Long-term management of chronic spontaneous urticaria with omalizumab. Clinical and Experimental Dermatology 42:7, pages 735-742.
Crossref
Crossref
A. Giménez-Arnau, M. Ferrer, J. Bartra, I. Jáuregui, M. Labrador-Horrillo, J. Ortiz de Frutos, J.F. Silvestre, J. Sastre, M. Velasco & A. Valero. (2017) Management of chronic spontaneous urticaria in routine clinical practice: A Delphi-method questionnaire among specialists to test agreement with current European guidelines statements. Allergologia et Immunopathologia 45:2, pages 134-144.
Crossref
Crossref
Joanna Goździk-Spychalska, Małgorzata Rzymkowska & Halina Batura-Gabryel. (2016) Pokrzywka przewlekła u chorej na ciężką astmę atopową – podwójna korzyść z leczenia omalizumabem. Alergologia Polska - Polish Journal of Allergology 3, pages S28-S30.
Crossref
Crossref
M.N. Ghazanfar, C. Sand & S.F. Thomsen. (2016) Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. British Journal of Dermatology 175:2, pages 404-406.
Crossref
Crossref
A. M. Giménez-Arnau, E. Toubi, A. M. Marsland & M. Maurer. (2016) Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology 30, pages 25-32.
Crossref
Crossref
M. Maurer, A.M. Giménez-Arnau & T. Zuberbier. (2016) What is new and upcoming in the world of chronic urticaria?. Journal of the European Academy of Dermatology and Venereology 30, pages 5-6.
Crossref
Crossref
Yasmin Moolani, Charles Lynde & Gordon Sussman. (2016) Advances in Understanding and Managing Chronic Urticaria. F1000Research 5, pages 177.
Crossref
Crossref
Paul Wilches, Paola Wilches, Juan Carlos Calderon, Annia Cherrez & Ivan Cherrez Ojeda. (2016) Omalizumab for chronic urticaria in Latin America. World Allergy Organization Journal 9, pages 36.
Crossref
Crossref
Luis Felipe Ensina, Solange Oliveira Rodrigues Valle, Ana Paula Juliani, Michel Galeane, Rosaly Vieira dos Santos, Luisa Karla Arruda, Janaina Michelle Lima Melo, Patrícia Karla de Souza, Faradiba Sarquis Serpa, Djanira Martins de Andrade, Alfeu Tavares França, Régis Albuquerque Campos, Inês Camelo-Nunes & Dirceu Solé. (2016) Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience. International Archives of Allergy and Immunology 169:2, pages 121-124.
Crossref
Crossref
Sinisa Savic, Alexander Marsland, David McKay, Michael R Ardern-Jones, Tabi Leslie, Olivier Somenzi, Laura Baldock & Clive Grattan. (2015) Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care. Allergy, Asthma & Clinical Immunology 11:1.
Crossref
Crossref
M. Maurer, M.K. Church, M. Gonçalo, G. Sussman & M. Sánchez-Borges. (2015) Management and treatment of chronic urticaria (CU). Journal of the European Academy of Dermatology and Venereology 29, pages 16-32.
Crossref
Crossref
M. Ferrer, J. Bartra, A. Giménez-Arnau, I. Jauregui, M. Labrador-Horrillo, J. Ortiz de Frutos, J. F. Silvestre, J. Sastre, M. Velasco & A. Valero. (2015) Management of urticaria: not too complicated, not too simple. Clinical & Experimental Allergy 45:4, pages 731-743.
Crossref
Crossref
Tse Wen Chang, Christina Chen, Chien-Jen Lin, Martin Metz, Martin K. Church & Marcus Maurer. (2015) The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology 135:2, pages 337-342.e2.
Crossref
Crossref
Allen P. Kaplan & Todor A. Popov. (2014) Biologic agents and the therapy of chronic spontaneous urticaria. Current Opinion in Allergy & Clinical Immunology 14:4, pages 347-353.
Crossref
Crossref
Karsten Weller & Marcus Maurer. 2014. Evidence-Based Dermatology. Evidence-Based Dermatology
210
222
.
R.A. Sabroe. (2014) Commentary: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. British Journal of Dermatology 171:1, pages 13-15.
Crossref
Crossref
D. Staumont-Sallé. (2014) Applications des biomédicaments dans la dermatite atopique et l’urticaire chronique. Revue Française d'Allergologie 54:3, pages 152-156.
Crossref
Crossref
Gordon Sussman, Jacques Hébert, Carly Barron, Jia Bian, Rose-Marie Caron-Guay, Stéphanie Laflamme & Simon Stern. (2014) Real-life experiences with omalizumab for the treatment of chronic urticaria. Annals of Allergy, Asthma & Immunology 112:2, pages 170-174.
Crossref
Crossref